US 2026/0274954 A1Published application

The novel monoclonal antibodies to programmed death 1 (pd-1)

AssigneeCstone Pharmaceuticals (Suzhou) Co., Ltd.

InventorsYong Zheng, Jing Li, Gennady Gololobov, Xinhua Zhang, Baotian Yang, Zhewei Tang, Dong Li, Jianqing Xu, Zhuozhi Wang

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.

Claims18

Dependent claims

An antibody or an antigen binding fragment thereof, comprising:

a) a variable region of a heavy chain having an amino acid sequence of SEQ ID NO:
1 and a variable region of a light chain having an amino acid sequence of SEQ ID NO:
3;
or
b) a variable region of a heavy chain having an amino acid sequence of SEQ ID NO:
2 and a variable region of a light chain having an amino acid sequence of SEQ ID NO:
3;
or
c) a variable region of a heavy chain having an amino acid sequence of SEQ ID NO:
2 and a variable region of a light chain having an amino acid sequence of SEQ ID NO:
4;
or
d) a variable region of a heavy chain having an amino acid sequence of SEQ ID NO:
2 and a variable region of a light chain having an amino acid sequence of SEQ ID NO:
5;
or
e) a variable region of a heavy chain having an amino acid sequence of SEQ ID NO:
1 and a variable region of a light chain having an amino acid sequence of SEQ ID NO:
6;
or
f) a variable region of a heavy chain having an amino acid sequence of SEQ ID NO:
1 and a variable region of a light chain having an amino acid sequence of SEQ ID NO:
5;
or
g) a variable region of a heavy chain having an amino acid sequence of SEQ ID NO:
2 and a variable region of a light chain having an amino acid sequence of SEQ ID NO:
6;
or
h) a variable region of a heavy chain having an amino acid sequence of SEQ ID NO:
2 and a variable region of a light chain having an amino acid sequence of SEQ ID NO:
7;
or
i) a variable region of a heavy chain having an amino acid sequence of SEQ ID NO:
1 and a variable region of a light chain having an amino acid sequence of SEQ ID NO:
8;
or
j) a variable region of a heavy chain having an amino acid sequence of SEQ ID NO:
2 and a variable region of a light chain having an amino acid sequence of SEQ ID NO:
9;
wherein the antibody specifically binds to PD-1.

37 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/447,981Filed 13 Jan 2026
Priority: 21 Sep 2016
Published: 17 Sep 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification17 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61P 35/00
Antineoplastic agents
C07K 16/2806
Against the immunoglobulin superfamily: against CD2
C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex

Family

Application16/333,993Continuation · filed 21 Sep 2016
Application17/853,606Division · filed 29 Jun 2022
Application18/459,236Continuation · filed 31 Aug 2023
Application19/447,981Continuation
Application18/459,236Division
Application17/853,606Continuation
US 11,414,487 B2Related patent
US 2020/0002420 A1Published application
US 2023/0014722 A1Published application
US 2024/0101676 A1Published application
US 2026/0274954 A1This patent

From the US filing history. Foreign family members aren’t listed.